.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Chubb
Accenture
Chinese Patent Office
Citi
Deloitte
McKesson
Cantor Fitzgerald
Farmers Insurance
Boehringer Ingelheim

Generated: July 24, 2017

DrugPatentWatch Database Preview

ZAROXOLYN Drug Profile

« Back to Dashboard

Which patents cover Zaroxolyn, and what generic Zaroxolyn alternatives are available?

Zaroxolyn is a drug marketed by Ucb Inc and is included in one NDA.

The generic ingredient in ZAROXOLYN is metolazone. There are nine drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the metolazone profile page.

Summary for Tradename: ZAROXOLYN

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list53
Clinical Trials: see list3
Patent Applications: see list2,547
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ZAROXOLYN at DailyMed

Pharmacology for Tradename: ZAROXOLYN

Drug ClassThiazide-like Diuretic
Physiological EffectIncreased Diuresis
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc
ZAROXOLYN
metolazone
TABLET;ORAL017386-001Approved Prior to Jan 1, 1982ABRXYesNo► Subscribe► Subscribe► Subscribe
Ucb Inc
ZAROXOLYN
metolazone
TABLET;ORAL017386-002Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe
Ucb Inc
ZAROXOLYN
metolazone
TABLET;ORAL017386-003Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Federal Trade Commission
Queensland Health
Baxter
Moodys
Medtronic
Daiichi Sankyo
Express Scripts
Boehringer Ingelheim
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot